Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

Phase 2 Terminated 48 enrolled Hope Biosciences Research Foundation River Oaks Hospital and Clinics · collab United Memorial Medical Center · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19. The study purpose is to evaluate the safety and efficacy of four IV infusions of either placebo or HB-adMSCs in subjects with COVID-19.

Timeline

Start: 2020-06-30
Primary completion: 2021-09-30
Completion: 2021-09-30

Outcome

Outcome not reported

Stopped: “No need to continue with the availability of the COVID-19 VACCINE”

Publications

de Dios C, Vij R, Kim H, Park H, Chang D. Safety of multiple intravenous infusions of adipose-derived mesenchymal stem cells for hospitalized cases of COVID-19: a randomized controlled trial. Front Med (Lausanne). 2023 Dec 22;10:1321303. doi: 10.3389/fmed.2023.1321303. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HB-adMSC	Cell therapy	1e+08 cells	Intravenous